Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leticia Hernandez Davila

Endocrinology, Diabetes & Metabolism Carolina, PR Medical Doctor

NPI 1750573408 CMS profile 306289

Km 13.3 Calle 4, Metro Pavia Clinic, Carolina, PR 00987

Open in the dashboard

General payments

$26,994

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leticia Hernandez Davila of Carolina, PR is reported in the CMS Open Payments database as having received $26,994 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,083 21
2024 General $1,717 23
2023 General $2,746 27
2022 General $3,601 47
2021 General $10,520 46
2020 General $1,994 32
2019 General $4,331 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leticia Hernandez Davila
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Leticia Hernandez Davila were reported at $2,083. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Leticia Hernandez Davila Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $4,331 $494 $123–$2,253 $163
2020 $1,994 $335 $85–$1,841 $114
2021 $10,520 $398 $88–$1,981 $132
2022 $3,601 $364 $88–$1,568 $149
2023 $2,746 $420 $113–$1,614 $160
2024 $1,717 $440 $121–$1,646 $164
2025 $2,083 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $11,800 66 payments
  2. AbbVie, Inc. $3,654 10 payments
  3. Janssen Pharmaceuticals, Inc $2,175 5 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $1,643 23 payments
  5. Amgen Inc. $1,476 13 payments
  6. Merck Sharp & Dohme Corporation $1,359 12 payments
  7. Novo Nordisk Inc $1,054 25 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $975 23 payments
  9. AstraZeneca Pharmaceuticals LP $768 26 payments
  10. Medtronic, Inc. $711 11 payments
  11. Other $1,379 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,316 217 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,236 7 payments
  3. Consulting Fee $5,670 5 payments
  4. Travel and Lodging $536 8 payments
  5. Education $236 10 payments
Products named General payments · program years 2019–2025
  1. SOLIQUA 100/33 Endocrine & Metabolic Diseases $7,168 34 payments
  2. TOUJEO $4,374 28 payments
  3. SYNTHROID $3,191 8 payments
  4. INVOKANA $2,175 5 payments
  5. Kerendia $1,643 23 payments
  6. TZIELD $1,197 10 payments
  7. STEGLATRO $1,197 6 payments
  8. JARDIANCE $911 20 payments
  9. MINIMED 780G $636 9 payments
  10. SOLIQUA 100/33 Diabetes $528 8 payments
  11. Other $7,456 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

3,804

Median for Endocrinology: 1,959

Drug cost

$695,657

Median for Endocrinology: $890,201

Branded share of claims

58.9%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trijardy Xr Empaglifloz/Linaglip/Metformin Brand 126 $87,699
Mounjaro Tirzepatide Brand 61 $67,622
Trulicity Dulaglutide Brand 59 $65,980
Jardiance Empagliflozin Brand 87 $63,354
Ozempic Semaglutide Brand 50 $62,712
Farxiga Dapagliflozin Propanediol Brand 79 $59,650
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 73 $48,106
Synthroid Levothyroxine Sodium Brand 854 $45,135
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 37 $33,076
Januvia Sitagliptin Phosphate Brand 26 $23,283

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$3,459

Medicare's payments for the services billed

Medicare patients

21

Average age 75

Services billed

50

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 71%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
  • SANOFI-AVENTIS U.S. LLC $264
$264 — —
TOUJEO
  • SANOFI-AVENTIS U.S. LLC $211
$211 — —
SOLIQUA 100/33
  • SANOFI-AVENTIS U.S. LLC $211
$211 37 —
Repatha
  • Amgen Inc. $125
$125 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $125
$125 26 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record